Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Appeals Court Reinstates Vioxx Securities Class Action Against Merck

Executive Summary

A federal appeals court concluded that shareholders did not wait too long to bring a securities class action against Merck alleging the company defrauded investors by failing to disclose safety problems with its pain reliever Vioxx

You may also be interested in...

Vioxx's Long Shadow: Supreme Court Skeptical Of Merck's Argument On Timing Of Securities Suits

Case could determine how much evidence is necessary for investors to bring a securities fraud suit to start the clock running on the statute of limitations.

Should FDA Warning Letter Prompt Securities Suit? Government, PhRMA Disagree

Supreme Court is to decide when Merck investors had sufficient information to sue for securities fraud; FDA warning letter about Vioxx risks is at issue.

Supreme Court Pick Sotomayor Lacks Rx Track Record, But Vioxx Case Looms

Those poring over Judge Sonia Sotomayor's rulings can get a sense of her views on civil rights, environmental law, privacy and the Second Amendment right to bear arms. But there seems to be no indication of how President Obama's nominee to the Supreme Court might rule on issues affecting the pharmaceutical industry

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts